Document is current
Any future updates will be listed below
-
Authors
Webb, Dominic-Luc https://orcid.org/0000-0002-6979-9194
Hage, Camilla https://orcid.org/0000-0002-4142-2416
Ljung-Faxén, Ulrika https://orcid.org/0000-0002-0223-1588
Pironti, Gianluigi https://orcid.org/0000-0001-9401-3029
Thorvaldsen, Tonje https://orcid.org/0000-0003-0637-4743
Andersson, Daniel C. https://orcid.org/0000-0003-4548-702X
Ståhlberg, Marcus https://orcid.org/0000-0003-0319-6240
Lund, Lars H. https://orcid.org/0000-0003-1411-4482
Hellström, Per M. https://orcid.org/0000-0001-8428-0772
-
Funding
Funding for this research was provided by:
Uppsala University
- License Information
-
More Information
Article History
Received: 4 June 2025
Accepted: 17 March 2026
First Online: 26 March 2026
Declarations
:
: Dominic-Luc Webb: Founder and senior consultant at DLW Bioanalytics® (academic CRO launched in 2025 dedicated to small and custom clinical chemistry). Camilla Hage : Consulting fees from Novartis, Roche Diagnostics, and AnaCardio; research grants from Bayer and speaker’s honoraria from MSD and Novartis. Ulrika Ljung-Faxen: Consulting fees AnaCardio, lecture fees Orion Pharma. Tonje Thorvaldsen: Lecture fees Orion Pharma, Boehringer Ingelheim, Abbott. Marcus Ståhlberg: Consulting fees, AnaCardio, Impulse dynamics, Swedish agency for health technology assessment and assessment of social services; Speaker’s honoraria: Medtronic, Orion Pharma, ALK-Nordic, Werfen. Lars H Lund: Grants: AstraZeneca, Vifor, Boston Scientific, Boehringer Ingelheim, Novartis.Consulting: Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon,Myokardia, Boehringer Ingelheim, Servier. Speaker’s honoraria: Abbott, MedScape, Radcliffe, AstraZeneca, Novartis. Stock ownership and founder: AnaCardio (a start-up company dedicated to developing acyl ghrelin analogues for the treatment of heart failure). Per M. Hellström: Consulting fees Pharmanovia, RenaPharma, Milltons.Remaining authors Gianluigi Pironti , and Daniel C. Andersson report no conflicts of interest.
